Amphastar Pharmaceuticals Profit Margin 2012-2023 | AMPH

Current and historical gross margin, operating margin and net profit margin for Amphastar Pharmaceuticals (AMPH) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Amphastar Pharmaceuticals net profit margin as of December 31, 2023 is 21.34%.
Amphastar Pharmaceuticals Annual Profit Margins
Amphastar Pharmaceuticals Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.889B $0.644B
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $14.328B 5.17
Dr Reddy's Laboratories (RDY) India $11.833B 18.71
Aspen Pharmacare (APNHY) South Africa $5.172B 0.00
BridgeBio Pharma (BBIO) United States $4.387B 0.00
Bausch Health Cos (BHC) Canada $3.143B 2.45
Supernus Pharmaceuticals (SUPN) United States $1.580B 0.00
Taysha Gene Therapies (TSHA) United States $0.451B 0.00
Generation Bio (GBIO) United States $0.185B 0.00
Assembly Biosciences (ASMB) United States $0.073B 0.00
Personalis (PSNL) United States $0.061B 0.00
Acasti Pharma (ACST) Canada $0.029B 0.00
Sol-Gel Technologies (SLGL) Israel $0.025B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00